Rea David J, Rosen Charles B, Nagorney David M, Heimbach Julie K, Gores Gregory J
Division of Transplantation Surgery, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Surg Oncol Clin N Am. 2009 Apr;18(2):325-37, ix. doi: 10.1016/j.soc.2008.12.008.
Liver transplantation for cholangiocarcinoma has historically been maligned. Because of a high recurrence rate and poor patient survival, the disease has been viewed as an absolute contraindication to transplantation. Based on good results using neoadjuvant and palliative radiation, a protocol for liver transplantation in selected patients with unresectable hilar cholangiocarcinoma was developed in 1993. Neoadjuvant radiation is followed by operative staging to rule out patients with lymph node metastases before liver transplantation. This approach has achieved results superior to standard surgical therapy, with 72% 5-year survival for patients with unresectable disease.
胆管癌的肝移植在历史上一直不被看好。由于复发率高且患者生存率低,这种疾病被视为移植的绝对禁忌证。基于新辅助放疗和姑息放疗取得的良好效果,1993年制定了针对部分无法切除的肝门部胆管癌患者的肝移植方案。新辅助放疗后进行手术分期,以排除肝移植前有淋巴结转移的患者。这种方法取得了优于标准手术治疗的效果,无法切除疾病患者的5年生存率为72%。